TORECAN
LOE ApproachingNDAORALTABLET
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is an oral small-molecule tablet approved by Novartis in 1961 with an unknown mechanism of action and indication profile. The drug is currently in a loss-of-exclusivity (LOE) approaching phase, indicating mature market status. Generic alternatives and competitive pressure are present in this therapeutic space.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TORECAN currently has zero linked job openings, reflecting its mature market status and approaching LOE. Career opportunities are limited and primarily defensive in nature, focusing on portfolio protection and managed decline rather than growth.
Brand ManagerField Sales Representative
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.